CA2955196A1 - N-methyl-d-aspartate receptor modulators and methods of making and using same - Google Patents

N-methyl-d-aspartate receptor modulators and methods of making and using same Download PDF

Info

Publication number
CA2955196A1
CA2955196A1 CA2955196A CA2955196A CA2955196A1 CA 2955196 A1 CA2955196 A1 CA 2955196A1 CA 2955196 A CA2955196 A CA 2955196A CA 2955196 A CA2955196 A CA 2955196A CA 2955196 A1 CA2955196 A1 CA 2955196A1
Authority
CA
Canada
Prior art keywords
group
independently selected
alkyl
ring atoms
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2955196A
Other languages
English (en)
French (fr)
Inventor
M. Amin Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naurex Inc
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of CA2955196A1 publication Critical patent/CA2955196A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2955196A 2014-07-24 2015-07-24 N-methyl-d-aspartate receptor modulators and methods of making and using same Abandoned CA2955196A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462028512P 2014-07-24 2014-07-24
US62/028,512 2014-07-24
US201562129388P 2015-03-06 2015-03-06
US62/129,388 2015-03-06
PCT/US2015/042070 WO2016014982A1 (en) 2014-07-24 2015-07-24 N-methyl-d-aspartate receptor modulators and methods of making and using same

Publications (1)

Publication Number Publication Date
CA2955196A1 true CA2955196A1 (en) 2016-01-28

Family

ID=55163858

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2955196A Abandoned CA2955196A1 (en) 2014-07-24 2015-07-24 N-methyl-d-aspartate receptor modulators and methods of making and using same

Country Status (6)

Country Link
US (2) US9994614B2 (enExample)
EP (2) EP3171941B1 (enExample)
JP (2) JP2017525684A (enExample)
AU (2) AU2015292324A1 (enExample)
CA (1) CA2955196A1 (enExample)
WO (1) WO2016014982A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107200725A (zh) * 2016-03-18 2017-09-26 江苏恒瑞医药股份有限公司 稠杂环类衍生物、其制备方法及其在医药上的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511459A (ja) * 2016-02-01 2019-04-25 ノーレックス インコーポレイテッド ジピロリジンペプチド化合物の合成プロセス
CN108148113A (zh) * 2016-12-06 2018-06-12 深圳先进技术研究院 一种nmda受体调控剂四肽衍生物的固相合成方法
CN107474107B (zh) * 2017-05-18 2023-01-17 江苏恩华药业股份有限公司 Glyx-13的制备方法及用于制备glyx-13的化合物
US20200199173A1 (en) * 2017-07-28 2020-06-25 Naurex, Inc. Process and intermediates for synthesis of peptide compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59104350A (ja) * 1982-11-10 1984-06-16 フアルムイタリア・カルロ・エルバ・ソシエタ・ペル・アチオ−ニ 生物学的に活性なペプチド及びその製造方法，該ペプチドを含む動物用成長促進剤
DE3618407A1 (de) * 1986-05-31 1987-12-03 Victor Dipl Chem Dr Med Brantl Pharmakologisch aktive peptide
US5763393A (en) * 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
CN101370509A (zh) * 2006-01-13 2009-02-18 安克瑞格公司 化合物连同γ辐射在用于治疗癌症中的应用
US20100130581A1 (en) * 2006-03-31 2010-05-27 The University Of Queensland Compounds and methods for the treatment of pain
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120178695A1 (en) * 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
US20110065648A1 (en) * 2009-09-15 2011-03-17 Maione Theodore E Advantageous mu-opiate receptor peptide compounds
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107200725A (zh) * 2016-03-18 2017-09-26 江苏恒瑞医药股份有限公司 稠杂环类衍生物、其制备方法及其在医药上的应用
CN107200725B (zh) * 2016-03-18 2021-06-29 江苏恒瑞医药股份有限公司 稠杂环类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
EP3171941A4 (en) 2018-03-21
JP2020176124A (ja) 2020-10-29
AU2021201006A1 (en) 2021-03-11
US9994614B2 (en) 2018-06-12
AU2015292324A1 (en) 2017-02-23
EP3171941A1 (en) 2017-05-31
US20170210779A1 (en) 2017-07-27
US20180258139A1 (en) 2018-09-13
JP2017525684A (ja) 2017-09-07
EP3916003A1 (en) 2021-12-01
WO2016014982A1 (en) 2016-01-28
AU2015292324A8 (en) 2017-03-30
EP3171941B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
AU2019204073B2 (en) NMDA receptor modulators and uses thereof
EP2951185B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3514158B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP2951182B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
AU2021201006A1 (en) N-methyl-D-aspartate receptor modulators and methods of making and using same
EP3490990B1 (en) Spiro-lactam nmda modulators and methods of using same
CA2898863A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
DE69426897T2 (de) Antithrombotisch wirkende azacycloalkyl-alkanoyl-peptide und-pseudopeptide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200715

FZDE Discontinued

Effective date: 20221115